Chai Discovery Raises $130M Series‑B, Valued at $1.3B

Key Takeaway

Chai Discovery, a start‑up backed by OpenAI, raised $130 million in a Series‑B round, valuing the company at $1.3 billion. This showcases how AI‑driven foundation models accelerate drug discovery and attract investors.

Summary

• Funding & valuation – Series‑B: $130 million; Valuation: $1.3 billion; Series‑A: $70 million (2024); Total funding: > $225 million.
• Investors – Lead: General Catalyst, Oak HC/FT; Others: Menlo Ventures, OpenAI, Dimension, Thrive Capital, Neo, Yosemite Venture Fund, Lachy Groom, SV Angel, Glade Brook, Emerson Collective.
• Company & team – Founded 2024 after co‑founder & CEO Josh Meier left OpenAI & Facebook; CEO: Josh Meier.
• Technology – Focus on AI‑friendly foundation models predicting biochemical interactions; Goal: “Computer‑Aided Design Suite” for molecules; First models: Chai 1, Chai 2; Chai 2 improves de‑novo antibody design.
• Medium & details – Article published on TechCrunch; Date: 15 Dec 2025, 3:41 PM PST; Image credit: Andrew Brooks.
• Context – Part of growing AI‑led biotech market.

Related queries

• Wie trägt Chai Discovery KI zur Beschleunigung der Wirkstoffentwicklung bei?
• Wer sind die Hauptinvestoren bei der Series‑B‑Finanzierung von Chai Discovery?
• Welche konkreten Fortschritte bietet das neue Chai 2‑Modell im Antikörper‑Design?

Quelle: TechCrunch Article